Condensed Consolidated Statements of Operations and Comprehensive Loss - USD ($) $ in Thousands		3 Months Ended
		Mar. 31, 2022	Mar. 31, 2021
REVENUES:
Total revenue		$ 43,158	$ 56,261
OPERATING EXPENSES:
Cost of sales - product		4,060	3,925
Cost of sales - intangible amortization		200	200
Research and development, net of amounts reimbursable	[1]	22,697	31,440
Selling, general and administrative		30,048	34,097
Loss from operations		(13,847)	(13,401)
OTHER INCOME (EXPENSE):
Other income (expense)		379	(1)
Interest expense		(4,822)	(4,364)
Interest income		14	57
Gain on extinguishment of debt		0	1,960
NET LOSS		(18,276)	(15,749)
OTHER COMPREHENSIVE LOSS:
Foreign currency gain		6	0
Unrealized loss from available-for-sale debt securities		0	(21)
COMPREHENSIVE LOSS		(18,270)	(15,770)
LOSS ATTRIBUTABLE TO COMMON STOCKHOLDERS - BASIC		(18,276)	(15,749)
LOSS ATTRIBUTABLE TO COMMON STOCKHOLDERS - DILUTED		$ (18,276)	$ (15,749)
LOSS PER SHARE:
Basic (in dollars per share)		$ (0.39)	$ (0.34)
Diluted (in dollars per share)		$ (0.39)	$ (0.34)
WEIGHTED AVERAGE SHARES:
Basic (in shares)		47,441,821	46,981,016
Diluted (in shares)		47,441,821	46,981,016
Product revenue, net
REVENUES:
Total revenue		$ 42,958	$ 45,261
License revenue
REVENUES:
Total revenue		$ 200	$ 11,000

[1] Amounts reimbursable were $9.1 million and $14.3 million for the three months ended March 31, 2022 and 2021, respectively.